Azienda Sanitaria Territoriale Di Pesaro E Urbino

The medical center is at the forefront of lung cancer research, focusing on innovative treatments for Non-Small Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC). The center's research aims to improve patient outcomes through advanced immunotherapy and chemoimmunotherapy approaches.

• PD-L1 high NSCLC treatments
• Chemoimmunotherapy for ES-SCLC
• KRAS G12C mutation therapies

By integrating cutting-edge therapies, the center is enhancing the efficacy and safety of treatments, offering hope to patients with advanced stages of lung cancer.

Specializing in gastric and gastroesophageal cancers, the center is pioneering research in HER2-positive cancer treatments. The focus is on the clearance of circulating tumor DNA (ctDNA) to improve patient prognosis post-surgery.

• HER2-positive gastric cancer therapies
• Minimal residual disease management

Through these studies, the center is advancing personalized medicine, tailoring treatments to individual genetic profiles for better outcomes.

The center is conducting pivotal research in metastatic colorectal cancer (mCRC), focusing on the efficacy of chemotherapy combinations with targeted therapies. This research aims to optimize first-line treatment strategies for patients with specific genetic mutations.

• RAS/BRAF mutation-targeted therapies
• Liquid biopsy advancements

By exploring these innovative approaches, the center is contributing to the development of more effective and less invasive treatment options for colorectal cancer patients.

Focusing on Acute Myeloid Leukemia (AML), the center is exploring novel treatment combinations to improve survival rates. Research includes the use of isocitrate dehydrogenase (IDH) inhibitors and azacitidine in patients not eligible for intensive chemotherapy.

• IDH mutation-targeted therapies
• Adjunctive treatments in HCT

These studies are paving the way for more personalized and effective treatment regimens, enhancing the quality of life for AML patients.

The center is advancing research in triple-negative breast cancer, focusing on the use of anti-PD-L1 antibodies as adjuvant therapy. This research aims to improve disease-free survival in high-risk patients post-surgery and chemotherapy.

• Adjuvant avelumab therapy
• High-risk breast cancer management

Through these efforts, the center is contributing to the development of more effective treatment strategies, offering new hope to breast cancer patients.